MP
SRPT icon

Mangrove Partners’s Sarepta Therapeutics SRPT Stock Holding History

Mangrove Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-492,500
Closed -$9.39M – 28
2016
Q2 		$9.39M Buy
+492,500
New +$9.12M 2.34% 13

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Mangrove Partners's SRPT Position: Q3 2016 in Review

Mangrove Partners sold out of Sarepta Therapeutics (SRPT) in Q3 2016, closing a stake of 492,500 shares — an estimated $9.39M sold.

Mangrove Partners first reported a position in SRPT in Q2 2016 and held it in 1 quarter. The position peaked at $9.39M in Q2 2016. 186 funds tracked by Wall St. Rank hold SRPT as of Q3 2016.

  • Mangrove Partners reported no remaining Sarepta Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Mangrove Partners sold 492,500 Sarepta Therapeutics shares in Q3 2016, an estimated $9.39M.
  • Mangrove Partners first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 1 quarter.
  • Mangrove Partners's Sarepta Therapeutics position peaked at $9.39M in Q2 2016.
  • 186 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2016.

Based on Mangrove Partners's 13F filing for Q3 2016, filed 14 Nov 2016.